big, i don't remember this, and i don't know where to begin. most will just be a repeat of the abstract.
1. based on a 9 year literature search it was found that a great number of pancreatic cancer were found to have hh pathways that were genetically altered based on genetic analysis. 2. use of an early version (first?) of a hhi has been shown to stop metatstasis, in vitro and in vivo. i am surprised by this statement. 3. shh has been shown to be involved with the growth of the dense fibrotic stroma in the tumour microenvironment; therefore an inhibitor may help penetration of the stroma/drug delivery to the tumour. 4. ligand-dependant activation by hh happens in the stroma via cell-to-cell signalling causing tumour growth (i think i have that right). 5. "Medications that destruct pancreatic cancer initiating stem cells are a potentially novel strategy in cancer treatment."